Page last updated: 2024-11-11

l 732531

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

32-O-(1-hydroxyethylindol-5-yl)ascomycin: a tacrolimus-related immunosuppressant with reduced toxicity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9876331
MeSH IDM0285738

Synonyms (10)

Synonym
l-732531
7VM80M10N6 ,
32-o-(1-hydroxyethylindol-5-yl)ascomycin
148365-48-4
indolyl-ascomycin
l-732,531
l 732531
unii-7vm80m10n6
(1r,9s,12s,13r,14s,17r,18z,21s,23s,24r,25s,27r)-17-ethyl-1,14-dihydroxy-12-[(1e)-1-[(1r,3r,4r)-4-{[1-(2-hydroxyethyl)-1h-indol-5-yl]oxy}-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]o
Q27268916

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The clinical usefulness of tacrolimus is limited, however, by severe adverse effects, including neurotoxicity and nephrotoxicity."( A tacrolimus-related immunosuppressant with reduced toxicity.
Barker, J; DaSilva, C; Dumont, FJ; Koo, G; Koprak, S; Parsons, WH; Pivnichny, J; Sigal, NH; Sinclair, PJ; Singer, I; Staruch, MJ; Talento, A; Williamson, AR; Wong, F; Woods, J; Wyvratt, M, 1998
)
0.3

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of L-732,531 in baboons was estimated at 3%, 9%, and 24% when animals were dosed at 5, 15, and 26 mg/kg po, respectively."( Disposition of L-732,531, a potent immunosuppressant, in rats and baboons.
Carey, KD; Chiu, SH; Colletti, A; Hawkins, T; Karanam, BV; Lavin, M; Miller, RR; Montgomery, T; Stearns, RA; Tang, YS; Vincent, SH, 1998
)
0.3

Dosage Studied

ExcerptRelevanceReference
"2 mg/kg to 30 ml/min/kg when dosed at 1 and 3 mg/kg."( Disposition of L-732,531, a potent immunosuppressant, in rats and baboons.
Carey, KD; Chiu, SH; Colletti, A; Hawkins, T; Karanam, BV; Lavin, M; Miller, RR; Montgomery, T; Stearns, RA; Tang, YS; Vincent, SH, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (80.00)18.2507
2000's1 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.40 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.20 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]